YU10500A - Supstituisani 4-okso-naptiridin-3-karboksamidi kao gaba moždani receptorski liganidi - Google Patents
Supstituisani 4-okso-naptiridin-3-karboksamidi kao gaba moždani receptorski liganidiInfo
- Publication number
- YU10500A YU10500A YU10500A YU10500A YU10500A YU 10500 A YU10500 A YU 10500A YU 10500 A YU10500 A YU 10500A YU 10500 A YU10500 A YU 10500A YU 10500 A YU10500 A YU 10500A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- substituted
- napthyridine
- carboxamides
- oxo
- agonists
- Prior art date
Links
- 210000004556 brain Anatomy 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 4
- 239000005557 antagonist Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 230000036626 alertness Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91818097A | 1997-08-25 | 1997-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU10500A true YU10500A (sh) | 2002-10-18 |
Family
ID=25439933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU10500A YU10500A (sh) | 1997-08-25 | 1998-08-24 | Supstituisani 4-okso-naptiridin-3-karboksamidi kao gaba moždani receptorski liganidi |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1007526A1 (enExample) |
| JP (1) | JP2001514181A (enExample) |
| KR (1) | KR20010023313A (enExample) |
| CN (1) | CN1268136A (enExample) |
| AP (1) | AP2000001742A0 (enExample) |
| AU (1) | AU753800B2 (enExample) |
| BG (1) | BG104192A (enExample) |
| BR (1) | BR9811362A (enExample) |
| CA (1) | CA2301599C (enExample) |
| EG (1) | EG21717A (enExample) |
| HU (1) | HUP0003258A3 (enExample) |
| IL (1) | IL134291A0 (enExample) |
| IS (1) | IS5382A (enExample) |
| LV (1) | LV12539B (enExample) |
| NO (1) | NO20000822L (enExample) |
| NZ (1) | NZ502548A (enExample) |
| OA (1) | OA11293A (enExample) |
| PE (1) | PE130999A1 (enExample) |
| PL (1) | PL338783A1 (enExample) |
| SI (1) | SI20270A (enExample) |
| SK (1) | SK2162000A3 (enExample) |
| TW (1) | TW574221B (enExample) |
| WO (1) | WO1999010347A1 (enExample) |
| YU (1) | YU10500A (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE289593T1 (de) * | 1999-05-06 | 2005-03-15 | Neurogen Corp | Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden |
| US6448246B1 (en) | 1999-05-25 | 2002-09-10 | Neurogen Corporation | Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US6562822B2 (en) | 2000-07-12 | 2003-05-13 | Pharmacia & Upjohn Company | Heterocyle carboxamides as antiviral agents |
| US6730682B2 (en) | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| EP1326611B1 (en) | 2000-10-12 | 2007-06-13 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| IL155089A0 (en) | 2000-10-12 | 2003-10-31 | Merck & Co Inc | Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| CA2425625A1 (en) | 2000-10-12 | 2002-07-18 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| US20020151591A1 (en) * | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| JP2004527500A (ja) * | 2001-03-01 | 2004-09-09 | ファイザー・プロダクツ・インク | 認識障害の治療のためのニコチン受容体部分アゴニスト、エストロゲン、選択的エストロゲン調節剤又はビタミンｅとｇａｂａａ逆アゴニストの併用 |
| AR036256A1 (es) | 2001-08-17 | 2004-08-25 | Merck & Co Inc | Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento |
| ATE370948T1 (de) | 2002-01-17 | 2007-09-15 | Merck & Co Inc | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen |
| WO2003077850A2 (en) | 2002-03-15 | 2003-09-25 | Merck & Co., Inc. | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors |
| WO2004106336A1 (en) * | 2003-05-27 | 2004-12-09 | Pfizer Products Inc. | Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides |
| WO2004106334A2 (en) * | 2003-05-28 | 2004-12-09 | Pfizer Products Inc. | Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation |
| DK2074123T3 (da) * | 2006-10-16 | 2013-01-14 | Bionomics Ltd | Nye anxiolytiske forbindelser |
| DK2083811T3 (en) * | 2006-11-22 | 2017-01-30 | Clinical Res Ass Llc | PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR204813A1 (es) * | 1972-05-08 | 1976-03-05 | Yamanouchi Pharma Co Ltd | Proceso para la preparacion de derivados de ampilicina |
| GB1433774A (en) * | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
| US4374138A (en) * | 1981-11-13 | 1983-02-15 | Warner-Lambert Company | Antibacterial amide compounds, compositions, and methods of use |
| DD279887A1 (de) * | 1987-07-03 | 1990-06-20 | Inst Pharmakologische Forschun | Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika |
| DD295360A5 (de) * | 1987-07-03 | 1991-10-31 | Akad Wissenschaften | Verfahren zur Herstellung von aktivierten Carbonsäureestern |
| DD279875A1 (de) * | 1987-07-03 | 1990-06-20 | Inst Pharmakologische Forschun | Verfahren zur herstellung von aktivierten carbonsaeureestern |
| JPS6461461A (en) * | 1987-09-01 | 1989-03-08 | Otsuka Pharma Co Ltd | Benzohetero ring derivative |
-
1998
- 1998-08-24 NZ NZ502548A patent/NZ502548A/en unknown
- 1998-08-24 AU AU91173/98A patent/AU753800B2/en not_active Ceased
- 1998-08-24 IL IL13429198A patent/IL134291A0/xx unknown
- 1998-08-24 CN CN98808578A patent/CN1268136A/zh active Pending
- 1998-08-24 HU HU0003258A patent/HUP0003258A3/hu unknown
- 1998-08-24 YU YU10500A patent/YU10500A/sh unknown
- 1998-08-24 EP EP98943352A patent/EP1007526A1/en not_active Withdrawn
- 1998-08-24 CA CA002301599A patent/CA2301599C/en not_active Expired - Fee Related
- 1998-08-24 SK SK216-2000A patent/SK2162000A3/sk unknown
- 1998-08-24 JP JP2000507675A patent/JP2001514181A/ja active Pending
- 1998-08-24 KR KR1020007001948A patent/KR20010023313A/ko not_active Withdrawn
- 1998-08-24 WO PCT/US1998/017513 patent/WO1999010347A1/en not_active Ceased
- 1998-08-24 BR BR9811362-3A patent/BR9811362A/pt not_active Application Discontinuation
- 1998-08-24 PL PL98338783A patent/PL338783A1/xx unknown
- 1998-08-24 SI SI9820055A patent/SI20270A/sl unknown
- 1998-09-29 EG EG118098A patent/EG21717A/xx active
- 1998-10-23 TW TW87117597A patent/TW574221B/zh active
- 1998-11-13 PE PE1998001100A patent/PE130999A1/es not_active Application Discontinuation
-
2000
- 2000-02-01 AP APAP/P/2000/001742A patent/AP2000001742A0/en unknown
- 2000-02-18 NO NO20000822A patent/NO20000822L/no not_active Application Discontinuation
- 2000-02-18 OA OA1200000044A patent/OA11293A/en unknown
- 2000-02-22 IS IS5382A patent/IS5382A/is unknown
- 2000-02-25 BG BG104192A patent/BG104192A/xx unknown
- 2000-03-16 LV LVP-00-29A patent/LV12539B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU9117398A (en) | 1999-03-16 |
| NO20000822L (no) | 2000-04-13 |
| WO1999010347A1 (en) | 1999-03-04 |
| SI20270A (sl) | 2000-12-31 |
| AP2000001742A0 (en) | 2000-02-24 |
| HUP0003258A3 (en) | 2001-05-28 |
| PL338783A1 (en) | 2000-11-20 |
| BG104192A (en) | 2001-05-31 |
| NO20000822D0 (no) | 2000-02-18 |
| KR20010023313A (ko) | 2001-03-26 |
| CA2301599C (en) | 2003-03-25 |
| NZ502548A (en) | 2002-06-28 |
| OA11293A (en) | 2002-11-19 |
| CA2301599A1 (en) | 1999-03-04 |
| LV12539B (en) | 2001-01-20 |
| HUP0003258A2 (en) | 2001-03-28 |
| SK2162000A3 (en) | 2001-03-12 |
| TW574221B (en) | 2004-02-01 |
| PE130999A1 (es) | 1999-12-16 |
| IL134291A0 (en) | 2001-04-30 |
| JP2001514181A (ja) | 2001-09-11 |
| BR9811362A (pt) | 2000-08-22 |
| CN1268136A (zh) | 2000-09-27 |
| LV12539A (en) | 2000-10-20 |
| IS5382A (is) | 2000-02-22 |
| EG21717A (en) | 2002-02-27 |
| AU753800B2 (en) | 2002-10-31 |
| EP1007526A1 (en) | 2000-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU10500A (sh) | Supstituisani 4-okso-naptiridin-3-karboksamidi kao gaba moždani receptorski liganidi | |
| OA09579A (en) | Certain imidazoquinoxalines a new class of gaba brain receptor ligands | |
| AU4818000A (en) | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands | |
| CA2175204A1 (en) | Certain Fused Pyrrolecarboxanilides; a New Class of GABA Brain Receptor Ligands | |
| NZ330861A (en) | Fused pyrrolecarboxamides and use as a new class of GABA brain receptor ligands | |
| DE60106641D1 (de) | Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten | |
| DE60014339T8 (de) | Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren | |
| NO20013001L (no) | 2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)kinoksalin-5(6H)on- derivater som er 5HT2C-agonister | |
| TW200510324A (en) | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist | |
| CA2091986A1 (en) | Certain cycloalkyl and azacycloalkyl pyrrolopyrimidines; a new class of gaba brain receptor ligands | |
| PT1666462E (pt) | Derivados de n-[1h-indol-5-il]-naftaleno-1-sulfonamida e compostos associados enquanto antagonistas do receptor 5- ht6 de serotonina para o tratamento de distúrbios do sistema nervoso central | |
| WO2002000623A3 (en) | Aryl fused substituted 4-oxy-pyridines | |
| WO1999043661A3 (en) | Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands | |
| AU2321597A (en) | Novel imidazo{1,5-c}quinazolines; a new class of gaba brain receptor ligands | |
| AP2002002420A0 (en) | Fused pyrrolecarboxamides: gaba brain receptor ligands. | |
| CA2223936A1 (en) | Novel substituted aryl and cycloalkyl imidazolones; a new class of gaba brain receptor ligands | |
| DE69926378D1 (de) | Oxo-pyridoimidazol-carboxamide: gaba-rezeptor-liganden im gehirn | |
| CA2249562A1 (en) | Certain fused pyrrolecarboxamides as gaba brain receptor ligands | |
| DE69907448D1 (de) | Pyrido[2,3-b]indolizinderivate und aza analoge: crf1 spezifische liganden | |
| MX9709771A (es) | Nuevas aril y cicloalquil imidazolonas substituidas, una clase de ligandos receptores de acido gamma-aminobutirico del cerebro. | |
| AR007742A1 (es) | Pirrolcarboxanilidas fusionadas; una nueva clase de ligandos receptores gaba del cerebro. | |
| YU35292A (sh) | Izvesni imidazohinoksalini nova klasa gaba moždanih receptorskih liganada |